PUBLICATION

Global Business Reports

AUTHORS

Germaine Aboud, Kolby Kaller

India Life Sciences 2023 Pre-Release Edition

November 25, 2022

GBR is excited to return to India to capture the growth of the country’s life sciences sector as it expands beyond its traditional role as a global supplier of affordable generics into a force of innovation in its own right. 

The pharmacy of the world, India is experiencing record export pharmaceutical volumes as its life sciences industry keeps pace with a rising global population rebounding from the most pressing case of unmet medical need in recent history — the outbreak of Covid-19. At the same time, innovations within sub-sectors including digital health and medical devices are enabling Indian companies to better penetrate large swaths of the country’s domestic population that have historically been beyond the reaches of centralized healthcare schemes. Furthermore, as consumers shift their focus from illness to wellness, nutraceuticals companies thrive in a post-pandemic environment. 

 

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

MACIG

Lindian Resources is extending its portfolio of assets in Africa from bauxite in Guinea to rare earths in Malawi.

SUBSCRIBE TO OUR NEWSLETTER